KALA Logo

Kala Pharmaceuticals, Inc. (KALA) 

NASDAQ
Market Cap
$32.25M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
594 of 776
Rank in Industry
35 of 47

Largest Insider Buys in Sector

KALA Stock Price History Chart

KALA Stock Performance

About Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative …

Insider Activity of Kala Pharmaceuticals, Inc.

Over the last 12 months, insiders at Kala Pharmaceuticals, Inc. have bought $0 and sold $323,513 worth of Kala Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Kala Pharmaceuticals, Inc. have bought $240.12M and sold $565,144 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 80 shares for transaction amount of $304 was made by Bazemore Todd (Chief Operating Officer) on 2020‑10‑22.

List of Insider Buy and Sell Transactions, Kala Pharmaceuticals, Inc.

2024-06-26SaleCHIEF EXECUTIVE OFFICER
15,168
0.5561%
$4.75$72,048+28.37%
2024-06-26SaleSEE REMARKS
5,489
0.2012%
$4.75$26,073+28.37%
2024-06-26SaleSEE REMARKS
4,653
0.1706%
$4.75$22,102+28.37%
2024-06-26SaleCHIEF FINANCIAL OFFICER
4,163
0.1526%
$4.75$19,774+28.37%
2024-06-26SaleCHIEF BUSINESS OFFICER
5,158
0.1891%
$4.75$24,501+28.37%
2024-05-31SaleCHIEF EXECUTIVE OFFICER
7,392
0.2379%
$6.09$45,017-12.05%
2024-05-31SaleSEE REMARKS
2,002
0.0644%
$6.09$12,192-12.05%
2024-05-31SaleSEE REMARKS
2,093
0.0673%
$6.09$12,746-12.05%
2024-05-31SaleCHIEF BUSINESS OFFICER
231
0.0074%
$6.09$1,407-12.05%
2024-05-31SaleCHIEF FINANCIAL OFFICER
1,786
0.0575%
$6.09$10,877-12.05%
2024-01-04SaleCHIEF EXECUTIVE OFFICER
4,539
0.1618%
$6.73$30,547-2.43%
2024-01-04SaleSEE REMARKS
1,617
0.0577%
$6.74$10,899-2.43%
2024-01-04SaleSEE REMARKS
1,227
0.0438%
$6.74$8,270-2.43%
2024-01-04SaleCHIEF FINANCIAL OFFICER
1,227
0.0438%
$6.74$8,270-2.43%
2024-01-04SaleCHIEF BUSINESS OFFICER
1,385
0.0494%
$6.73$9,321-2.43%
2024-01-04SaleSEE REMARKS
1,405
0.0502%
$6.74$9,470-2.43%
2023-01-04SaleCHIEF EXECUTIVE OFFICER
198
0.0065%
$28.54$5,651-66.29%
2023-01-04SaleSEE REMARKS
73
0.0024%
$28.53$2,083-66.29%
2023-01-04SaleSEE REMARKS
62
0.002%
$28.54$1,769-66.29%
2023-01-04SaleCHIEF FINANCIAL OFFICER
60
0.002%
$28.54$1,712-66.29%

Insider Historical Profitability

<0.0001%
Bazemore ToddSEE REMARKS
83040
1.8023%
$7.0039<0.0001%
RA CAPITAL MANAGEMENT, L.P.
10874613
236.0162%
$7.0030<0.0001%
Shah Rajeev M.
7039613
152.7836%
$7.0032<0.0001%
ORBIMED ADVISORS LLC10 percent owner
3447840
74.8299%
$7.00140<0.0001%
Grunberg Gregorydirector
2534854
55.015%
$7.0030<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$2.12M5.98266,6130%+$00.02
Millennium Management LLC$1.05M2.99133,403+0.55%+$5,715.36<0.01
Ubs Oconnor Llc$568,823.001.6372,554New+$568,823.000.03
The Vanguard Group$334,589.000.9441,981+49.74%+$111,149.76<0.0001
BlackRock$216,601.000.6127,177-0.53%-$1,147.68<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.